Log In Sign up
The largest database of trusted experimental protocols

Oleic acid albumin complex

Manufactured by Merck Group
Visit Supplier

Oleic acid-albumin complex is a laboratory reagent composed of oleic acid bound to the protein albumin. It serves as a source of fatty acids for the cultivation and growth of cells in cell culture applications.

Automatically generated - may contain errors

Lab products found in correlation

Blastomyces dermatitidis, by American Type Culture Collection (3 mentions) Middlebrook 7h10 agar, by Merck Group (2 mentions)

Spelling variants of this product

Oleic acid (1560 citations) Oleic acid-albumin (9 citations) Oleic acid-albumin-dextrose complex (3 citations) Albumins ( (2 citations)

10 protocols using oleic acid albumin complex

1

Virulent B. dermatitidis Yeast Culture

Cited 2 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
Strains used were wild-type, virulent B. dermatitidis ATCC strain 26199, DsRed26199 [35 (link)] and strain #55, the isogenic, attenuated mutant lacking BAD1 [36 (link)]. B. dermatitidis was grown as yeast on Middlebrook 7H10 agar with oleic acid-albumin complex (Sigma) at 39°C.
Wang H., Lee T.J., Fites S.J., Merkhofer R., Zarnowski R., Brandhorst T., Galles K., Klein B, & Wüthrich M. (2017). Ligation of Dectin-2 with a novel microbial ligand promotes adjuvant activity for vaccination. PLoS Pathogens, 13(8), e1006568.
+ Open protocol
+ Expand
2

Blastomyces dermatitidis Vaccination and Challenge

Check if the same lab product or an alternative is used in the 5 most similar protocols
The wild-type virulent strain of Blastomyces dermatitidis was purchased from American Type Culture Collection (ATCC; strain #26199). The isogenic, attenuated mutant lacking BAD1 (strain #55) was used for all vaccinations[38 (link)]. Isolates of B. dermatitidis were cultured and maintained as yeast on Middlebrook 7H10 agar with oleic acid-albumin complex (Sigma-Aldrich) at 39°C. Mice were vaccinated with B. dermatitidis strain #55 (~5 x 105cfu) subcutaneously at two sites, dorsally and at the base of tail. For challenge studies, the virulent B. dermatitidis strain #26199 (~104 cfu) was inoculated intratracheally. To ennumerate fungal burden, lung tissue was homogenized and plated on brain heart infusion (BHI; Difco) agar.
Nanjappa S.G., McDermott A.J., Fites J.S., Galles K., Wüthrich M., Deepe GS J.r, & Klein B.S. (2017). Antifungal Tc17 cells are durable and stable, persisting as long-lasting vaccine memory without plasticity towards IFNγ cells. PLoS Pathogens, 13(5), e1006356.
+ Open protocol
+ Expand
3

Cultivation of Pathogenic Fungi

Check if the same lab product or an alternative is used in the 5 most similar protocols
Wild-type, virulent B. dermatitidis ATCC strain 26199 was used for this study and grown as yeast on Middlebrook 7H10 agar with oleic acid-albumin complex (Sigma) at 39°C. Virulent C. albicans yeast of ATCC strain SC5314 were used in some experiments and grown as yeast on YPD agar or broth at 30°C. C. neoformans var. grubii strain KN99 were maintained as glycerol stocks -80C and initially cultured on YPD agar at 30°C.
dos Santos Dias L., Dobson H.E., Bakke B.K., Kujoth G.C., Huang J., Kohn E.M., Taira C.L., Wang H., Supekar N.T., Fites J.S., Gates D., Gomez C.L., Specht C.A., Levitz S.M., Azadi P., Li L., Suresh M., Klein B.S, & Wüthrich M. (2021). Structural basis of Blastomyces Endoglucanase-2 adjuvancy in anti-fungal and -viral immunity. PLoS Pathogens, 17(3), e1009324.
+ Open protocol
+ Expand
4

Virulent B. dermatitidis Strains for Vaccination

Check if the same lab product or an alternative is used in the 5 most similar protocols
Wild-type virulent B. dermatitidis strain 26199 was purchased from ATCC. An isogenic attenuated mutant lacking BAD-I (strain #55) and recombinant #55 strain carrying the OT-I epitope SIINFEKL were also used for vaccination (below). Isolates were maintained as yeast on Middlebrook 7H10 agar with oleic acid-albumin complex (Sigma-Aldrich, St. Louis, MO) at 39°C.
Nanjappa S.G., Hernández-Santos N., Galles K., Wüthrich M., Suresh M, & Klein B.S. (2015). Intrinsic MyD88-Akt1-mTOR Signaling Coordinates Disparate Tc17 and Tc1 Responses during Vaccine Immunity against Fungal Pneumonia. PLoS Pathogens, 11(9), e1005161.
+ Open protocol
+ Expand
5

Maintenance of Blastomyces dermatitidis Strains

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
B. dermatitidis strains used were American Type Culture
Collection (ATCC) 26199, a wild type virulent strain, and the isogenic,
attenuated mutant lacking BAD1, designated strain 55 (11 (link)). Isolates of B. dermatitidiswere maintained as yeast on Middlebrook 7H10 agar with oleic acidalbumin complex
(Sigma Chemical Co., St. Louis, MO) at 39°C.
Kohn E.M., dos Santos Dias L., Dobson H.E., He X., Wang H., Klein B.S, & Wüthrich M. (2022). SLAMF1 is dispensable for vaccine induced T cell development but required for resistance to fungal infection. Journal of immunology (Baltimore, Md. : 1950), 208(6), 1417-1423.
+ Open protocol
+ Expand
6

Blastomyces dermatitidis Virulent and Attenuated Strains

Check if the same lab product or an alternative is used in the 5 most similar protocols
The wild-type virulent strain of Blastomyces dermatitidis is obtained from American Type Culture Collection, #26199. The isogenic strain #55, an attenuated mutant lacking BAD1 (kindly provided by Bruce Klein, UW-Madison), was used for vaccination. Isolates of both strains were maintained as yeast on Middlebrook 7H10 agar supplemented with oleic acid-albumin complex (Sigma-Aldrich) at 39°C.
Mudalagiriyappa S., Sharma J., Vieson M.D, & Nanjappa S.G. (2022). GM-CSF+ Tc17 cells are required to bolster vaccine immunity against lethal fungal pneumonia without causing overt pathology. Cell reports, 41(4), 111543.
+ Open protocol
+ Expand
7

Cultivation and Characterization of Dimorphic Fungi

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
B. dermatitidis strains used were American Type Culture Collection (ATCC) 26199, a wild type virulent strain, and the isogenic, attenuated mutant lacking BAD1, designated strain #55 (39 (link)). Isolates of B. dermatitidis were maintained as yeast on Middlebrook 7H10 agar with oleic acid-albumin complex (Sigma Chemical Co., St. Louis, MO) at 39°C. H. capsulatum strain G217B (generously provided by George S. Deepe, University of Cincinnati, Cincinnati, OH) was maintained on Brain Heart Infusion (BHI) slants supplemented with 5% sheep blood at 37°C. C. posadasii isolate C735 is a virulent, human clinical strain that was used to generate a live, attenuated vaccine strain (ΔT) by deleting the chitinases 2, 3 and D-arabinotol-2-dehydrogenase genes as previously described (3 ). The saprobic phase of both the parental and mutant strains were grown on GYE medium (1% glucose, 0.5% yeast extract, 1.5% agar) at 30°C for 3–4 weeks to generate a confluent layer of arthroconidia (spores) on the agar surface. Formalin-killed endosporulated spherules of C. posadasii were generated as described (40 (link)).
Wang H., LeBert V., Hung C.Y., Galles K., Saijo S., Lin X., Cole G.T., Klein B.S, & Wüthrich M. (2014). C-type lectin receptors differentially induce Th17 cells and vaccine immunity to the endemic mycosis of North America. Journal of immunology (Baltimore, Md. : 1950), 192(3), 1107-1119.
+ Open protocol
+ Expand
8

Vaccination against Blastomyces and Histoplasma

Cited 2 times
Check if the same lab product or an alternative is used in the 5 most similar protocols
Wild-type virulent strains of Blastomyces dermatitidis (#26199) and Histoplasma capsulatum (G217B) were obtained from ATCC. The isogenic attenuated strain of Blastomyces lacking the virulence factor BAD1 (#55) (23 (link)) was used for vaccination (105-106 CFU). Blastomyces was maintained as yeast on Middlebrook 7H10 agar supplemented with Oleic acid-albumin complex (Sigma) at 39° C. To measure OT-I T cell responses, recombinant #55 strain engineered to carry the OT-I epitope, SIINFEKL, was used for vaccination (106 CFUs) (19 (link)). Histoplasma capsulatum was maintained on Histoplasma Macrophage Medium (HMM) slants and used for vaccination (107 CFU). To study vaccine resistance, mice were challenged intratracheally (i.t.) with ~104 CFUs of virulent strain B. dermatitidis (#26199). Vaccinations were given subcutaneously (s.c.), divided at two sites, one dorsally and one at the base of tail (3 (link), 24 (link)).
Nanjappa S.G., Mudalagiriyappa S., Scott Fites J., Suresh M, & Klein B.S. (2018). CBLB constrains inactivated vaccine-induced CD8+ T cell responses and immunity against lethal fungal pneumonia. Journal of immunology (Baltimore, Md. : 1950), 201(6), 1717-1726.
+ Open protocol
+ Expand
9

Cultivation of Virulent B. dermatitidis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Wild-type, virulent B. dermatitidis ATCC strain 26199 was used for this study and grown as yeast on Middlebrook 7H10 agar with oleic acid-albumin complex (Sigma) at 39°C.
Wüthrich M., Dobson H.E., Ledesma Taira C., Okaa U.J., dos Santos Dias L., Isidoro-Ayza M., Petrovsky N, & Klein B.S. (2021). Combination Adjuvants Enhance Recombinant Protein Vaccine Protection against Fungal Infection. mBio, 12(4), e02018-21.
+ Open protocol
+ Expand
10

Blastomyces dermatitidis Virulent and Attenuated Strains

Check if the same lab product or an alternative is used in the 5 most similar protocols
The wild-type virulent strain of Blastomyces dermatitidis is obtained from American Type Culture Collection, #26199. The isogenic strain #55, an attenuated mutant lacking BAD1 (kindly provided by Bruce Klein, UW-Madison), was used for vaccination. Isolates of both strains were maintained as yeast on Middlebrook 7H10 agar supplemented with oleic acid-albumin complex (Sigma-Aldrich) at 39°C.
Mudalagiriyappa S., Sharma J., Vieson M.D, & Nanjappa S.G. (2022). GM-CSF+ Tc17 cells are required to bolster vaccine immunity against lethal fungal pneumonia without causing overt pathology. Cell reports, 41(4), 111543.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!